---
title: "MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292763424.md"
description: "MediciNova announced that its NIH-funded SEANOBI-ALS expanded-access study of MN-166 (ibudilast) has reached its target enrollment of 200 patients. The program provides the drug to ALS patients ineligible for randomized clinical trials under the ACT for ALS initiative. Final patient follow-ups are expected to conclude in early 2027, with subsequent data analysis planned for scientific presentations and peer-reviewed publications."
datetime: "2026-07-15T12:03:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292763424.md)
  - [en](https://longbridge.com/en/news/292763424.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292763424.md)
generator: "portal-rs"
---

# MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target

-   MediciNova reached its 200-patient target enrollment in the NIH-funded SEANOBI-ALS expanded-access study of MN-166 (ibudilast) in ALS. \* Program supplies MN-166 to ALS patients ineligible for ongoing randomized clinical trials under the ACT for ALS initiative. \* Final patient follow-ups are projected to end in early 2027, with data analysis planned to support scientific presentations and peer-reviewed publications. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150800PRIMZONEFULLFEED9761981) on July 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)
- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)

## Related News & Research

- [Why the AI boom has become an election problem](https://longbridge.com/en/news/297766132.md)
- [Transgene says TG4050 posts 100% 3-year disease-free survival in Phase 1 head-and-neck cancer trial](https://longbridge.com/en/news/297809436.md)
- [Alumis says Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus misses primary endpoint](https://longbridge.com/en/news/297644348.md)
- [12:32 ETBOC Group im Gartner® Magic Quadrant™ 2026 für Digital Twin of an Organization Platforms als Challenger ausgezeichnet](https://longbridge.com/en/news/298060523.md)
- [Warner Music Stock And The Copyright Fight Reshaping Music Rights Investing](https://longbridge.com/en/news/297543553.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**